Will COVID-19 Vaccinations End Discrimination against COVID-19 Patients in China? New Evidence on Recovered COVID-19 Patients

Li, Lü; Wang, Jian; Leng, Anli; Nicholas, Stephen; Maitland, Elizabeth; Liu, Rugang

doi:10.3390/vaccines9050490

Cited by 14 publications

(28 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding showed higher agreement on supporting compulsory vaccination when is compared to a Western Asia study which indicated only around one third of healthcare workers supporting compulsory COVID-19 vaccine for all citizens and residents [20]. However, the compulsory COVID-19 vaccination may raise legally enforceable [21] or any stigmatization or discrimination happened afterward [22]. All of these should be explored in further studies for discussion.…”

Section: Discussionmentioning

confidence: 76%

COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses

Wong

Cheung

et al. 2021

Vaccines

View full text Add to dashboard Cite

Background: Vaccine hesitancy represents one of the major global health issues around the world. We examined the perception, attitude, perceived barriers and facilitation measures of receiving the COVID-19 vaccine in a Chinese population with free vaccine choices (Sinovac [Coronavac] vs. BioNTech/Fosun [Comirnaty]) and adequate doses. Method: We conducted a random telephone survey of the general population in 1195 subjects aged 18 years or above from 23 April 2021 to 8 May 2021 after two months of vaccine rollout. A descriptive analysis of the levels of enabling factors, obstacles and perception of COVID-19 vaccination was conducted using ANOVA and Chi-square tests for trend. Results: Only 10.1% and 13.5% had received one and two COVID-19 vaccine doses, respectively. Among those who had not received any COVID-19 vaccine (75.4%), only 25.1% expressed their intention to receive in the coming 6 months. The barriers with the highest scores included “having heard of cases with serious adverse events or death after vaccination” (score: 8.17 out 10, 95% C.I. 7.99, 8.35), “lack of confidence on governmental recommendations” (7.69, 95% C.I. 7.47, 7.91), and “waiting for a better vaccine” (7.29, 95% C.I. 7.07, 7.52). The highest score for the impact of various incentives for vaccination was for “vaccine passports for overseas travel” (4.44, 95% C.I. 4.18, 4.71). Conclusions: Vaccine hesitancy is commonly observed in this Chinese population despite adequate provision of vaccine doses and choices. No single incentive is strong enough to promote vaccination, and multiple facilitation measures for different groups of population are needed to encourage vaccine uptake. Active clarification and promotion by medical professionals together with a variety of incentives are needed to drive vaccine uptake.

show abstract

Section: Discussionmentioning

confidence: 76%

COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses

Wong

Cheung

et al. 2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…There were 16 studies from Africa [ 14 , 24 , 59 , 68 – 73 , 75 – 79 , 84 , 88 ], 25 studies from Asia [ 22 , 60 , 61 , 64 – 66 , 74 , 80 , 81 , 83 , 86 , 87 , 90 – 95 , 97 – 99 , 101 , 102 , 104 , 105 ], and others were conducted in Europe [ 67 , 89 , 96 ], North America [ 62 , 63 , 85 , 100 , 103 ] and South America [ 82 ]. More than half (27 studies) of the studies were conducted within community populations [ 22 , 60 , 66 , 69 – 72 , 74 , 76 , 79 – 81 , 83 , 85 – 88 , 90 , 91 , 93 , 95 , 99 – 104 ], while others consisted of health care workers (13 studies) [ 60 , 61 , 63 , 64 , 67 , 77 , 78 , 84 , 89 , 92 , 94 , 96 , 105 ] and patients (eight studies) [ 14 , …”

Section: Resultsmentioning

confidence: 99%

A systematic review and meta-analysis on the prevalence of stigma in infectious diseases, including COVID-19: a call to action

et al. 2021

View full text Add to dashboard Cite

Infectious diseases, including COVID-19, are crucial public health issues and may lead to considerable fear among the general public and stigmatization of, and discrimination against, specific populations. This meta-analysis aimed to estimate the pooled prevalence of stigma in infectious disease epidemics. We systematically searched PubMed, PsycINFO, Embase, MEDLINE, Web of Science, and Cochrane databases since inception to June 08, 2021, and reported the prevalence of stigma towards people with infectious diseases including SARS, H1N1, MERS, Zika, Ebola, and COVID-19. A total of 50 eligible articles were included that contributed 51 estimates of prevalence in 92722 participants. The overall pooled prevalence of stigma across all populations was 34% [95% CI: 28−40%], including enacted stigma (36% [95% CI: 28−44%]) and perceived stigma (31% [95% CI: 22−40%]). The prevalence of stigma in patients, community population, and health care workers, was 38% [95% CI: 12− 65%], 36% [95% CI: 28−45%], and 30% [95% CI: 20−40%], respectively. The prevalence of stigma in participants from low- and middle-income countries was 37% [95% CI: 29−45%], which is higher than that from high-income countries (27% [95% CI: 18−36%]) though this difference was not statistically significant. A similar trend of prevalence of stigma was also observed in individuals with lower education (47% [95% CI: 23−71%]) compared to higher education level (33% [95% CI: 23−4%]). These findings indicate that stigma is a significant public health concern, and effective and comprehensive interventions are needed to counteract the damaging effects of the infodemics during infectious disease epidemics, including COVID-19, and reduce infectious disease-related stigma.

show abstract

“…However, as the epidemic has spread, inaccurate information about COVID-19 has become widely available and transmitted, including material that underestimates the severity of the pandemic and information that minimizes the negative repercussions of the pandemic [36] , [37] , [38] , [39] . In an effort to fight the virus, several researchers are attempting to accelerate the research and production of COVID-19 vaccinations as quickly as possible [40] , [41] , [42] . In pre-clinical research now, around 195 vaccines are being tested, with a further 144 vaccines in clinical development as of February 18, 2022 [43] .…”

Section: Related Workmentioning

confidence: 99%